Natixis’s Aimmune Therapeutics AIMT Stock Holding History

Natixis’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-12,446	Closed	-$396K	–	1033
2018 Q1	$396K	Buy	+12,446	New	+$438K	﹤0.01%	695

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Natixis's AIMT Position: Q2 2018 in Review

Natixis sold out of Aimmune Therapeutics (AIMT) in Q2 2018, closing a stake of 12,446 shares — an estimated $396K sold.

Natixis first reported a position in AIMT in Q1 2018 and held it in 1 quarter. The position peaked at $396K in Q1 2018. 151 funds tracked by Wall St. Rank hold AIMT as of Q2 2018.

Natixis reported no remaining Aimmune Therapeutics position as of Q2 2018 after selling out during the quarter.
Natixis sold 12,446 Aimmune Therapeutics shares in Q2 2018, an estimated $396K.
Natixis first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 1 quarter.
Natixis's Aimmune Therapeutics position peaked at $396K in Q1 2018.
151 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2018.

Based on Natixis's 13F filing for Q2 2018, filed 14 Aug 2018.